Health and Healthcare
Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)
Published:
We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity. Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:
STOCK (Ticker) Shares Short Change
Amgen (AMGN) 29,112,550 +10.89%
Biogen Idec (BIIB) 6,648,180 (9.58%)
Celgene (CELG) 25,751,400 +12.19%
Genzyme (GENZ) 6,536,150 +12.36%
Gilead (GILD) 25,557,168 (1.59%)
Imclone (IMCL) 4,252,342 (13.49%)
Medarex (MEDX) 30,181,760 (7.72%)
As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.
Jon C. Ogg
December 11, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
